Universal Beteiligungs und Servicegesellschaft mbH Invests $3.04 Million in GoodRx Holdings, Inc. $GDRX

Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in GoodRx Holdings, Inc. (NASDAQ:GDRX) in the third quarter, Holdings Channel.com reports. The institutional investor purchased 717,660 shares of the company’s stock, valued at approximately $3,036,000.

A number of other institutional investors have also recently bought and sold shares of GDRX. XTX Topco Ltd lifted its position in shares of GoodRx by 281.2% in the 2nd quarter. XTX Topco Ltd now owns 272,273 shares of the company’s stock valued at $1,356,000 after acquiring an additional 200,852 shares in the last quarter. LSV Asset Management purchased a new position in GoodRx during the 2nd quarter worth approximately $1,900,000. Connor Clark & Lunn Investment Management Ltd. raised its stake in GoodRx by 16.5% during the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,671,521 shares of the company’s stock valued at $8,324,000 after purchasing an additional 236,896 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of GoodRx in the second quarter valued at $981,000. Finally, Vontobel Holding Ltd. purchased a new stake in shares of GoodRx in the second quarter valued at $58,000. Hedge funds and other institutional investors own 63.77% of the company’s stock.

GoodRx Trading Up 0.4%

Shares of NASDAQ GDRX opened at $2.34 on Thursday. The business has a 50 day simple moving average of $2.72 and a 200 day simple moving average of $3.61. GoodRx Holdings, Inc. has a 52 week low of $2.27 and a 52 week high of $5.81. The stock has a market cap of $794.27 million, a price-to-earnings ratio of 26.00, a PEG ratio of 0.89 and a beta of 1.45. The company has a debt-to-equity ratio of 0.81, a quick ratio of 3.11 and a current ratio of 3.11.

GoodRx (NASDAQ:GDRX) last issued its quarterly earnings data on Tuesday, November 4th. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.01). The business had revenue of $196.03 million for the quarter, compared to the consensus estimate of $195.17 million. GoodRx had a net margin of 3.97% and a return on equity of 9.73%. GoodRx’s revenue was up .4% compared to the same quarter last year. During the same period in the previous year, the business posted $0.08 EPS. On average, research analysts predict that GoodRx Holdings, Inc. will post 0.13 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently weighed in on the company. Morgan Stanley dropped their price target on GoodRx from $5.00 to $4.00 and set an “equal weight” rating on the stock in a research report on Thursday, December 18th. Barclays initiated coverage on GoodRx in a research note on Monday, December 8th. They set an “underweight” rating and a $3.00 target price on the stock. Weiss Ratings reissued a “sell (d)” rating on shares of GoodRx in a research report on Tuesday, December 23rd. JPMorgan Chase & Co. lowered their price objective on shares of GoodRx from $6.00 to $5.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 11th. Finally, Citigroup dropped their price objective on shares of GoodRx from $5.00 to $4.50 and set a “buy” rating on the stock in a research note on Friday, January 9th. Five equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $4.73.

About GoodRx

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.